Dr. Reddy’s, Amgen Enter Strategic Marketing Pact

Dr. Reddy’s Labs Ltd. has entered into a strategic collaboration with Amgen to market and distribute three Amgen products in India in the areas of oncology and cardiology.

Dr. Reddy’s will provide regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India.
 
Alok Sonig, Dr. Reddy’s executive vice president and head of India Business & Global Business Development said, “We are excited about our strategic collaboration with an innovation powerhouse like Amgen and look forward to making their innovative medicines accessible to Indian patients. Addressing significant unmet needs of patients in oncology and cardiovascular are key areas in India and, therefore, a priority for us at Dr. Reddy’s. We believe that good health can’t wait and that this is an important milestone for us in our journey as we improve patient care.”
 
“We are pleased to be joining forces with Dr. Reddy’s Laboratories in order to make Amgen’s innovative medicines available to patients in India,” said Penny Wan, Amgen vice president and general manager, Japan Asia Pacific Region. “Dr. Reddy’s has significant experience serving oncology and cardiovascular patients in India and shares Amgen’s interest in delivering new treatment options to seriously ill patients.”